EMA Authorised: Ponvory (ponesimod) — Laboratoires Juvisé Pharmaceuticals

View source ↗

Summary

The European Medicines Agency authorised Ponvory (ponesimod) for relapsing-remitting multiple sclerosis, with Laboratoires Juvisé Pharmaceuticals as the marketi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• PONVORY (PONESIMOD)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Laboratoires Juvisé Pharmaceuticals. Decision date: 12/02/2026